Revenio Group stock
REG1V.HEHELRevenio Group Oyj, HealthcareISIN FI0009010912
47Score 47 out of 100, Weak
Price and trend
27 / 100
Price history
−62% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 36% below it.
Since August 2025 the 50-day line has been below the 200-day line; the trend has turned down.
Sharply down: the price has fallen very quickly lately (RSI 27).
The price is 62% below its 52-week high. Largest decline in 20 years: 97% (October 2007 to June 2009).
Chart figures for advanced users
- SMA 50$12.04
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$15.58
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)27
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$9.96
- The lowest closing price of the last twelve months.
- Resistance$26.15
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Revenio Group Oyj belongs to the Medical (Devices) industry (Finland) and, with a market value of $419.17M, is number 82 of 88 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $121.56M (up 6% year on year) and earnings of $19.28M (down 5.9%).
- For fiscal 2026, analysts expect on average revenue of $220.59M (up 81.5%) and adjusted earnings per share of $0.63 (down 14%).
Show more
- MEQIRI Score 47 out of 100 (Weak): rank 422 of 702 in Healthcare, median 53.
- The P/E is 20.5 (Medical (Devices) median 29.1, own median of recent years 42.8).
- Our model puts fair value at $13.26, with the price 25% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 75
- Modestly valuedP/E 20.5, Medical (Devices) median 29.1, own median 42.8.Valuation 71
- High return on capitalReturn on invested capital 19.5% in fiscal 2025, Medical (Devices) median 5.4%.Profitability 60
Weaknesses
- Share price fell sharplyDown 61% over the last 12 months.Momentum 12
- High debtDebt 1.73 times equity (latest quarter), Medical (Devices) median 0.47.Stability 44
- Volatile share priceVolatility 69% a year over the last 12 months.Stability 44
Its standout strengths are fundamentals and valuation, while capital allocation and momentum hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price far below its 52-week high
- weak momentum
What lowers it
- price not overheated over the past year
Valuation
Valuation signal
Modestly undervaluedIn our model the price counts as cheap below $8.84 and expensive above $26.52 (uncertainty very high, based on the price swings of the past year).
The two parts of the fair value come to $12.35 (cash-flow model) and $14.17 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 10.8%. At 11.8% the fair value would be $12.55, at 9.8% it would be $14.16.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (29.1).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 15.6% on the twelve months before. Revenue has grown solidly since 2004, at about 10% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 43%, operating 23%, net 16%. Last 12 months: net 11%.
Debt & balance sheet
latest quarterMeaningfully leveraged, but the interest bill is comfortably covered.
Earnings
- Next earnings
- 11 Feb 2027in 90 days
- Last reported
- 12 Nov 2026EPS reported $0.11 (expected $0.11)in line with expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 7.0% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $0.63−0.1%
- Revenue
- $220.59M−0.1%
- Earnings per share
- $0.80−7.0%
- Revenue
- $296.07M+0.4%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook lowered
Share price after the results: −15.4%2026 guidance of net sales of EUR 190 million to EUR 205 million with profitability only at a satisfactory level, which an analyst describes as clearly lower than the original guidance from the winter.
“In top line, we guide currency rate adjusted net sales to be between EUR 190 million up to EUR 205 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 8 Sep 2026 (fiscal Q2 2026), read by AI.
What happened at Revenio Group
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 47
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Devices)
The next larger and next smaller companies by market value
- Ion Beam ApplicationsIBAB.BR $555.09M58
- Avita MedicalRCEL $500.03M47
- CellaVisionCEVI.ST $483.11M80
- Metall ZugMETN.SW $460.29M40
- NeuroPaceNPCE $412.58M32
- ImplanticaIMP-A-SDB.ST $400.4M50
- CerusCERS $391.79M33
- StratecSBS.DE $360.32M52
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 2 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.